CA3191163A1 — Fused tricyclic pyrimidine-thieno-pyridine small molecule inhibitors of ubiquitin-specific protease 28
Assigned to Dana Farber Cancer Institute Inc · Expires 2022-02-17 · 4y expired
What this patent protects
The present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof. The present disclosure further relates to methods of treating a disease or disorder associated with ubiquitin-specific protease 28 (USP28) and methods of inhibiting USP28.
USPTO Abstract
The present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof. The present disclosure further relates to methods of treating a disease or disorder associated with ubiquitin-specific protease 28 (USP28) and methods of inhibiting USP28.
Drugs covered by this patent
- Briviact (BRIVARACETAM) · UCB
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.